Jan 10, 2025 | Drug costs, Drug reimportation, News
Pharmaceutical companies are planning to increase prices on over 250 brand-name medications in the United States at the beginning of 2025, according to an analysis by health care research firm 3 Axis Advisors. That’s a notable drop from last January, during...
Oct 29, 2024 | Alternative Reimbursement Strategies, Chronic conditions, Client Report, Cost projections, Cost Savings, Direct-to-Employer Contracting, Drug costs, Fair market reimbursement, Forensic claims review, Health care costs, High-cost claims, MedBen Rx, MedBen WellLiving, Prescription, Rx Costs, Transparency, Trend, Wellness
Health care costs in the United States are projected to see their steepest rise in over a decade during 2025, with multiple industry analyses forecasting increases between 7% and 8% year-over-year (see table below). However, MedBen offers solutions that directly...
Oct 15, 2024 | Benefits preservation, Biosimilars, Cost Savings, Drug costs, High-cost claims, Rx Costs, Specialty Drugs
Specialty drugs continue to drive up pharmacy costs, accounting for over 50% of total drug spend for many self-funded health plans, despite being used by a small percentage of patients. But pharmaceutical and administrative solutions are available to help reduce that...
Sep 27, 2024 | Drug advertising, Drug costs, Pharmacy, Rebates, Study
KFF Health News warns consumers not to take TV drug ads at face value: “A 2023 study found that, among top-selling drugs, those with the lowest levels of added benefit tended to spend more on advertising to patients than doctors. ‘I worry that...
Sep 3, 2024 | Biosimilars, Cost Savings, Drug costs, GLP-1s, Humira, Mounjaro, Ozempic, Rx Costs, Savings, Trulicity, Wegovy
Humira continued to be the costliest prescription drug for self-funded health plans in 2023 by a comfortable margin, according to a recent Milliman commercial drug trends review. Used to treat a variety of conditions from Crohn’s to rheumatoid arthritis and psoriatic...
Apr 16, 2024 | Biosimilars, Cost Savings, Drug costs, Humira, MedBen Rx, Pharmacy, Prescription, Rx Costs, Savings
Last year, MedBen Rx announced a new program that would enable clients to purchase Idacio, a biosimilar version of the anti-inflammatory therapy Humira – a drug that typically costs between $6,000 and $12,000 per month depending on the dose – for under $1,000 per...
